HealthQuill Lung CAncer
Novartis AG will buy a US-based biotechnology company Mariana Oncology to expand its cancer portfolio for $1 billion.
Drugs Health Pharma

Novartis AG to buy Mariana Oncology for $1 billion to build RLT assets

HQ Team May 2, 2024: Novartis AG will buy a US-based biotechnology company Mariana Oncology to expand its cancer portfolio for $1 billion..

Read More
AstraZeneca’s lung cancer drug, Tagrisso, reduced the risk of death by 51% in the early stages of the disease, according to a company statement.
Drugs Medical Pharma

UK researchers get $2.1 million to develop lung cancer vaccine

HQ Team March 23, 2024: Researchers in the UK have won a grant of $2.14 million (€1.98 million) from the Cancer Research UK.

Read More
More than 35 million people may have cancer in 2050 — an increase of 77% from 20 million new cases in 2022, according to a WHO report.
Drugs Health Pharma

Cancer cases set to rise by 77% to 35 million in 2050: WHO global survey

More than 35 million people may have cancer in 2050 — an increase of 77% from 20 million new cases in 2022, according.

Read More
Bristol Myers Squibb, one of the world’s largest pharmaceutical companies, will acquire Mirati Therapeutics for $5.8 billion through a combination of cash and debt to broaden its cancer portfolio.
Drugs Health Pharma

Bristol Myers acquires Mirati Therapeutics for $5.8 billion

HQ Team October 9, 2023: Bristol Myers Squibb, one of the world’s largest pharmaceutical companies, will acquire Mirati Therapeutics for $5.8 billion through.

Read More
Delcath Systems Inc., has been granted an FDA nod for its Hepzato Kit, a liver-directed treatment for patients with metastatic uveal melanoma, giving the Delaware-based firm $60 million fund access.
Drugs Health Pharma

Delcath Systems gets FDA nod for Hepzato Kit to treat uveal melanoma

HQ Team August 16, 2023: Delcath Systems Inc., has been granted an FDA nod for its Hepzato Kit, a liver-directed treatment for patients.

Read More
AstraZeneca’s lung cancer drug, Tagrisso, reduced the risk of death by 51% in the early stages of the disease, according to a company statement.
Drugs Health Medical Pharma

AstraZeneca’s drug cuts risk of lung cancer death by 51%, trials show

HQ Team June 5, 2023: AstraZeneca’s lung cancer drug, Tagrisso, reduced the risk of death by 51% in the early stages of the.

Read More